MedTrace Logo

Fisetin in Mild Alzheimer's Disease

NCT07279714 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-04-13

No results posted yet for this study

Summary

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Conditions

  • Alzheimer s Disease
  • Alzheimer Dementia
  • Alzheimer Dementia (AD)
  • Alzheimer Disease
  • Mild Cognitive Disorder
  • Neurocognitive Disorders, Mild
  • Neurocognitive Disorder

Interventions

OTHER

Fisetin

Fisetin 20mg/kg/day

Sponsors & Collaborators

  • Sunnybrook Research Institute

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Krista Lanctôt, PhD · Sunnybrook Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-27
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07279714 on ClinicalTrials.gov